手术切除的非小细胞肺癌患者无复发生存率:系统文献综述与荟萃分析
该系统综述与荟萃分析检索2011年1月至2021年6月MEDLINE、EMBASE和Cochrane数据库,纳入471项研究、1060个手术组,分析60695例I-III期NSCLC患者的术后无复发生存率(RFS)。结果显示I期RFS从术后1年96%降至5年82%,III期从1年68%降至5年34%;年龄较大、男性比例较高、分期较晚、肿瘤较大及北美/欧洲地区与更差RFS显著相关。
要点
- I期NSCLC术后RFS从1年96%降至5年82%,III期从1年68%降至5年34%。
- 年龄较大、男性比例高、分期晚、肿瘤大及北美/欧洲地区与更差RFS相关。
- 仅用第八版分期标准的研究RFS估计略高于混合使用第七/八版的研究。
核心结论
- 该研究提供了NSCLC术后多个时间点及按地理区域分层的RFS综合估计,可辅助治疗决策和临床试验设计。
研究设计与样本
- 系统检索MEDLINE、EMBASE和Cochrane数据库(2011年1月至2021年6月),纳入471项研究共1060个手术组。
- 采用单臂随机效应荟萃分析计算效应估计及95%CI,并按AJCC分期标准分层分析。
- 对60695例使用第七或第八版分期标准的患者进行RFS分析。
主要发现
- I期患者RFS从术后1年96%降至5年82%。
- III期患者RFS从术后1年68%降至5年34%。
- 仅使用第八版分期标准的研究RFS估计略高于混合使用第七/八版的研究。
- 年龄较大、男性比例较高、分期较晚、肿瘤较大及北美/欧洲地区与更差RFS显著相关。
临床怎么用
- 可为NSCLC术后患者随访强度和复发监测策略提供参考依据。
- 有助于临床医生与患者沟通术后不同时间点的复发风险。
- 研究结果可用于设计以RFS为终点的临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard treatment for early-stage or locoregionally advanced non-small cell lung cancer (NSCLC) includes surgical resection. Recurrence after surgery is commonly reported, but a summary estimate for postsurgical recurrence-free survival (RFS) in patients with NSCLC is lacking. RESEARCH QUESTION: What is the RFS after surgery in patients with stage I-III NSCLC at different time points, and what factors are associated with RFS? STUDY DESIGN AND METHODS: A systematic search was performed in MEDLINE, EMBASE, and Cochrane databases between January 2011 and June 2021. The primary outcome was RFS at 1, 2, 3, and 5 years postresection. Single-arm, random-effects meta-analyses were done to calculate effect estimates and 95% CIs. Analyses were stratified by stage/substage as per the AJCC Cancer Staging Manual, and RFS was estimated (1) after pooling studies, using seventh or eighth edition staging criteria; and (2) among studies using only the eighth edition. Meta-regressions were performed to assess associations between RFS and patient demographic/clinical characteristics of interest. RESULTS: Data from 471 studies comprising 1,060 surgical study arms were extracted. RFS estimates from 60,695 patients staged with the seventh or eighth edition were analyzed. RFS ranged from 96% at 1 year postresection to 82% at 5 years for stage I, and from 68% at 1 year to 34% at 5 years for stage III. Estimates for patients staged using only eighth edition criteria were slightly higher. Older age, higher percentage of male patients, advancing stage, larger tumor size, and geographic region (North America/Europe vs Asia) were significantly associated with worse RFS. INTERPRETATION: This study presents a comprehensive assessment of reported RFS from published clinical literature, offering estimates at multiple postsurgical time points and by geographic region. Findings can inform treatment decisions, clinical trial design, and future research to improve outcomes among patients with NSCLC.
引用
- Rajaram R, Huang Q, Li RZ, et al. Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis. Chest. 2023. PMID: 38065405. doi:10.1016/j.chest.2023.11.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。